20180924 MyVac EN
Category: dates
Transgene Presents 2018 Half-Year Results and Business Update
20180919 H1 2018 RESULTS EN
Transgene Announces Upcoming Investor Meetings
20180903 PR financial agenda H2 18
Transgene completes the sale of the Greater China rights of TG6002 and TG1050 to Tasly Biopharmaceuticals for $48 million in newly-issued shares
180820 – TG Tasly Closing EN
Transgene and Tasly Biopharmaceuticals conclude strategic agreements for the rights of TG6002 and TG1050 in Greater China
180710 – TG Tasly agreement PR
Transgene’s Lead Oncolytic Virus Pexa-Vec Triggers Strong Anti-Tumor Immunity after Intravenous Administration
20180604 PR ASCO Pexa-vec neoadjuvant data EN
Transgene Announces Upcoming Investor Meetings
20180524 PR financial meetings Q2 18
Combined General Meeting of May 23, 2018
20180523 TG AGM 2018 EN
Single intravenous preoperative administration of the oncolytic virus Pexa-Vec to prime anti-tumor immunity
Alan Anthoney, et al. ASCO 2018, June 2018 – Abstract available on the ASCO website Download the poster here Poster Presentation
Transgene to Present New Clinical Data on Oncolytic Virus Pexa-Vec at ASCO 2018
20180517 PR ASCO poster accepted EN